Baird Downgrades Auspex Pharmaceuticals (ASPX) to Neutral
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
William Blair Downgrades Auspex Pharmaceuticals (ASPX) to Market Perform
March 31, 2015 7:09 AM EDTWilliam Blair downgraded Auspex Pharmaceuticals (NASDAQ: ASPX) from Outperform to Market Perform.
For an analyst ratings summary and ratings history on Auspex Pharmaceuticals click here. For more ratings news on Auspex Pharmaceuticals click here.
Shares of Auspex Pharmaceuticals closed at $100.36 yesterday.
... MoreStifel Downgrades Auspex Pharmaceuticals (ASPX) to Hold
March 31, 2015 7:07 AM EDTStifel downgraded Auspex Pharmaceuticals (NASDAQ: ASPX) from Buy to Hold.
For an analyst ratings summary and ratings history on Auspex Pharmaceuticals click here. For more ratings news on Auspex Pharmaceuticals click here.
Shares of Auspex Pharmaceuticals closed at $100.36 yesterday.
... MoreTeva Pharma (TEVA) to Acquire Auspex Pharma (ASPX) in $3.2B Deal
March 30, 2015 7:02 AM EDTTeva Pharma (NYSE: TEVA) and Auspex Pharmaceuticals, Inc. (Nasdaq: ASPX), today announced that they have entered into a definitive merger agreement under which Teva will commence a tender offer for all of the outstanding shares of Auspex at $101.00 per share in cash, representing total consideration of approximately $3.2 billion in enterprise value and approximately $3.5 billion in equity value. This transaction is expected to enhance Tevas revenue and earnings growth profile and strengthen its core central nervous system (CNS) franchise with the addition of Auspexs portfolio of innovative... More
